Overview of secondary liver cancer care pathways, key treatment steps, and the situations where dendritic cell treatment may be discussed as a selected option.
The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet therapies. Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explores ...
To date, human anti-tumor vaccination has not delivered on its promises. Reasons for failure include tumor immune escape mechanisms, limited availability of tumor specific antigens, as well as failure ...
From mutation to medicine: How neoantigen dendritic cell vaccines are reshaping cancer immunotherapy
Overview of the manufacturing process of personalized neoantigen-based DC vaccines. A typical basic process of manufacturing neoantigen-based DC vaccines by using monocyte-derived dendritic cells is ...
CD123 is universally and highly expressed on BPDCN cells. Because CD123 expression is significantly lower on normal hematopoietic stem cells, it provides a distinct "therapeutic window," allowing for ...
TOKYO -- Over 90% of physicians deny the scientific efficacy of nonstandard cancer treatments not covered by public medical insurance, according to a ･･･ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results